← Leaderboards
Geoffrey Scott Gottlieb
University Of Washington
$16,750,227
Attributed
$19,786,333
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,786,333 · 4
By mechanism
R01$19,206,643 · 3
K08$579,690 · 1
Top collaborators
- Paul K Drain5 shared
- Lisa M Frenkel5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Nancy Logan Haigwood$37,253,957
- Ann Cornwall Collier$29,777,747
- James J Champoux$6,575,588
- Shiu-Lok Hu$65,602,557
- Robert Vessella$14,829,966
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1ProgramsDrug ResistancePhenotypeViral Load ResultAntiretroviral TherapyInfectionResistanceCaringNon-Nucleoside Reverse Transcriptase InhibitorsRegimenAfricaGenotypeViralResistance MutationHiv-2Anti-Retroviral AgentsMutationSenegalAcquired Immunodeficiency SyndromePredispositionIntegraseEffectivenessResources
Grant awards (32)
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$594,778
R01 · FY2025 · AI · contact PI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$185,410
R01 · FY2025 · AI · contact PI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$725,239
R01 · FY2024 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$780,602
R01 · FY2023 · AI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$737,364
R01 · FY2023 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$1,219,140
R01 · FY2022 · AI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$737,364
R01 · FY2022 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$819,182
R01 · FY2021 · AI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$733,927
R01 · FY2021 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$834,531
R01 · FY2020 · AI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$754,817
R01 · FY2020 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$900,704
R01 · FY2019 · AI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$721,973
R01 · FY2019 · AI · contact PI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$721,973
R01 · FY2018 · AI · contact PI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$721,973
R01 · FY2017 · AI · contact PI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$745,812
R01 · FY2016 · AI · contact PI
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection$776,203
R01 · FY2015 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$667,733
R01 · FY2014 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$638,891
R01 · FY2013 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$689,435
R01 · FY2012 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$697,505
R01 · FY2011 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$722,944
R01 · FY2010 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$640,799
R01 · FY2009 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$629,187
R01 · FY2008 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$628,409
R01 · FY2007 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$643,001
R01 · FY2006 · AI · contact PI
Antiretroviral Therapy for HIV-2 Infection in Senegal$537,747
R01 · FY2005 · AI
Epidemiology of HIV-1/HIV-2 Dual Infection$120,258
K08 · FY2005 · AI
Epidemiology of HIV-1/HIV-2 Dual Infection$120,258
K08 · FY2004 · AI
Epidemiology of HIV-1/HIV-2 Dual Infection$120,258
K08 · FY2003 · AI
Epidemiology of HIV-1/HIV-2 Dual Infection$109,458
K08 · FY2002 · AI
Epidemiology of HIV-1/HIV-2 Dual Infection$109,458
K08 · FY2001 · AI